{"id":"NCT03104413","sponsor":"AbbVie","briefTitle":"A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-18","primaryCompletion":"2020-11-30","completion":"2021-05-19","firstPosted":"2017-04-07","resultsPosted":"2022-06-14","lastUpdate":"2022-06-14"},"enrollment":618,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"placebo for risankizumab IV","otherNames":[]},{"type":"DRUG","name":"risankizumab SC","otherNames":["ABBV-066 BI 655066","SKYRIZI"]},{"type":"DRUG","name":"risankizumab IV","otherNames":["ABBV-066 BI 655066","SKYRIZI"]}],"arms":[{"label":"Risankizumab Dose 1 (Induction Period 1)","type":"EXPERIMENTAL"},{"label":"Risankizumab Dose 2 (Induction Period 1)","type":"EXPERIMENTAL"},{"label":"Placebo (Induction Period 1)","type":"PLACEBO_COMPARATOR"},{"label":"Risankizumab Dose 1 (Induction Period 2)","type":"EXPERIMENTAL"},{"label":"Risankizumab Dose 2 (Induction Period 2)","type":"EXPERIMENTAL"},{"label":"Risankizumab Dose 3 (Induction period 2)","type":"EXPERIMENTAL"}],"summary":"The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active CD.","primaryOutcome":{"measure":"US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo (Induction Period 1)","deltaMin":19.8,"sd":null},{"arm":"Risankizumab 600mg (Induction Period 1)","deltaMin":42,"sd":null},{"arm":"Risankizumab 1200mg (Induction Period 1)","deltaMin":40.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"< 0.001"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":403,"countries":["United States","Argentina","Australia","Austria","Belarus","Belgium","Bosnia and Herzegovina","Bulgaria","Canada","Chile","China","Colombia","Croatia","Czechia","Denmark","Egypt","Estonia","France","Germany","Greece","Ireland","Israel","Italy","Latvia","Lithuania","Malaysia","Mexico","Netherlands","New Zealand","Poland","Portugal","Romania","Russia","Serbia","Singapore","Slovakia","South Africa","South Korea","Spain","Switzerland","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["39802486","39485390","39131711","37368103","35644154"],"seeAlso":["https://www.rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":207},"commonTop":["HEADACHE","ARTHRALGIA","NASOPHARYNGITIS","CROHN'S DISEASE","NAUSEA"]}}